Memorial Sloan-Kettering was one of the first centers to use this type of genetic testing for lung cancer patients and is currently one of the only centers testing for mutations in squamous cell carcinomas of the lung.

Research at Memorial Sloan-Kettering will benefit from renewed support for The Starr Cancer Consortium and the Tri-Institutional Stem Cell Initiative totaling $105 million.

Dr. Jarnagin – a surgeon who treats patients with disorders of the pancreas, liver, and bile ducts – discusses the specialized expertise of surgeons at Memorial Sloan-Kettering, a high-volume center.

Memorial Sloan-Kettering researchers have found that people in the late stages of cancer might benefit from meaning-centered psychotherapy, a treatment aimed at helping people sustain a sense of meaning and purpose.

Researchers have demonstrated a technique that enables specific and accurate labeling of brain tumor tissue in mice. If proven effective in patients, the method could make complete surgical removal of brain tumors more feasible.

In an article describing the history and promise of immunotherapy for cancer treatment, the magazine highlights the groundbreaking work of James Allison, Chair of the Sloan-Kettering Institute’s Immunology Program, and medical oncologist and immunologist Jedd Wolchok.